Company Filing History:
Years Active: 2017-2024
Title: Manuel Krispin: Innovator in Cancer Prognosis
Introduction
Manuel Krispin is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of cancer research through his innovative methods and nucleic acids aimed at determining the prognosis of cancer subjects. With a total of 4 patents, his work has the potential to improve the diagnosis and treatment of cancer patients.
Latest Patents
Krispin's latest patents focus on methods and nucleic acids for determining the prognosis of a cancer subject. These inventions provide essential tools, including genomic sequences and methylation patterns, which are crucial for the improved detection of cancer. By utilizing these advancements, healthcare professionals can enhance the diagnosis and treatment options available to patients suffering from this disease.
Career Highlights
Throughout his career, Manuel Krispin has worked with prominent companies in the field of diagnostics, including Epigenomics AG and New Day Diagnostics, LLC. His experience in these organizations has allowed him to develop and refine his innovative approaches to cancer prognosis.
Collaborations
Krispin has collaborated with esteemed colleagues such as Jörn Lewin and Dimo Dietrich. These partnerships have further enriched his research and contributed to the advancements in cancer prognosis methodologies.
Conclusion
Manuel Krispin's work in cancer prognosis exemplifies the impact of innovation in medical research. His patents and collaborations highlight the importance of continued advancements in the fight against cancer.